1 citations
,
July 2023 in “Cancers” Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.
December 2022 in “Journal of The American Academy of Dermatology” Low-dose oral minoxidil combined with topical minoxidil improves hair growth in breast cancer patients with therapy-induced hair loss.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” Dutasteride is the most effective for hair loss but may cause sexual and mental side effects.
2 citations
,
October 2021 in “Exploration of targeted anti-tumor therapy” Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.
12 citations
,
March 2021 in “Patient Preference and Adherence” Patients and oncologists prioritize survival benefits, while payers focus on treatment costs.
10 citations
,
December 2020 in “Dermatologic Therapy” Minoxidil and spironolactone combo effectively treats androgenetic alopecia, improving hair density and diameter.
10 citations
,
May 2020 in “Journal of The American Academy of Dermatology” Taking spironolactone doesn't increase the chance of breast cancer coming back.
53 citations
,
February 2020 in “Expert Opinion on Pharmacotherapy” Finasteride and minoxidil work best together for hair loss.
58 citations
,
September 2019 in “EMBO Molecular Medicine” CDK4/6 inhibitors can protect hair cells from chemotherapy damage.
4 citations
,
May 2019 in “Journal of Clinical Oncology” Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
22 citations
,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
53 citations
,
April 2018 in “Journal of The American Academy of Dermatology” Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
67 citations
,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
48 citations
,
September 2013 in “Oncologist” Endocrine therapies for cancer significantly increase the risk of hair loss.
125 citations
,
May 2007 in “Journal of The American Academy of Dermatology” The BASP classification is a detailed and accurate way to categorize hair loss in both men and women.